Immuno-oncology therapies are designed to help the patient’s own immune system fight tumors by transforming quiescent anti-tumor immune cells into targeted, cancer-specific killer cells.
Immuno-oncology therapies include immune cell therapies (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines, and cancer vaccines. ApoCell’s integrated platform technologies are designed to advance immuno-therapy candidates from pre-clinical discovery through phase III clinical trials using both tumor biopsies and liquid biopsies with less sample requirements to generate the type of data needed for assessing efficacy.
Tumor Biopsy – Immunohistochemistry and Immunofluorescence Image Analysis
ApoCell is uniquely positioned to help researchers interrogate tumors by combining our expertise in immunohistochemistry (IHC) and multiplex immunofluorescence (IF) image analysis detection. We offer conventional IHC validation for the detection of your markers of interest (including immune markers such as PDL1), and pathological scoring for real-time patient enrollment into clinical trials.
Our customizable, multiplex immuno-oncology IF panels enable a deeper understanding of the role of immune cells within solid tumors and their tumor microenvironment. We can customize any of our validated panels by adding exploratory biomarkers to perform quantitative image analysis using our Perkin Elmer Vectra Polaris high-throughput, multispectral image analysis platform. Using Perkin Elmer’s Opal reagent detection system, we can identify novel immune cell infiltrates in formalin-fixed paraffin embedded (FFPE) and tissue microarrays (TMAs).
Liquid Biopsy – Profiling CTCs and Immunophenotyping Immune Cells from the same sample
Our integrated platform technology approach along with our proprietary ApoStream technology enables the isolation of CTCs, immune cells, and other rare cells from the same sample for further downstream profiling. Following ApoStream enrichment, CTCs can be further characterized for expression of immune cell targets, eg, PDL-1, PDL-2, etc., using our customized Perkin Elmer Vectra Polaris workflow. The immune cells from the same sample can be simultaneously profiled using our customized multiplex IF flow cytometry panels. Together, this workflow provides an economical and beneficial approach to evaluating the therapeutic effects on both the tumor cells and immune cell interaction.
Obtaining serial tissue biopsies to monitor the effects of immuno-oncology therapies on immune cells within the tumor microenvironment can be very challenging, if not possible in some cancer types. Using our ApoStream technology, we can isolate CTCs from serial blood samples to perform transcriptomic analysis of CTCs including DNA microarrays and next-generation sequencing (NGS) and RNA-Seq. Transcription can also be studied at the level of individual cells by single-cell transcriptomics.